| Title |
Profile of Xeomin® (incobotulinumtoxinA) for the treatment of blepharospasm
|
|---|---|
| Published in |
Clinical Ophthalmology, June 2011
|
| DOI | 10.2147/opth.s13978 |
| Pubmed ID | |
| Authors |
Juwan Park, Michael S Lee, Andrew R Harrison |
| Abstract |
Even though conventional botulinum neurotoxin (BoNT) products have shown successful treatment results in patients with benign blepharospasm (BEB), the main, potential long-term side effect of BoNT use is the development of immunologic resistance due to the production of neutralizing antibody to the neurotoxin after repeated injections. Xeomin(®) (incobotulinumtoxinA), a unique botulinum neurotoxin type A (BoNT/A) drug free of complexing proteins otherwise contained in all conventional BoNT/A drugs, was recently approved by US Food and Drug Administration for the treatment of cervical dystonia or blepharospasm in adults. The newly approved BoNT/A drug may overcome this limitation of previous conventional products, since it contains pure neurotoxin (150 kDa) through a manufacturing process that separates it from complexing proteins such as hemagglutinins produced by fermentation of Clostridium botulinum. Many studies have also shown that Xeomin(®) has the same efficacy and safety profile as complexing protein-containing products such as Botox(®) and is exchangeable with Botox(®) using a simple 1:1 conversion ratio. Xeomin(®) represents a new treatment option for the repeated treatment of patients with blepharospasm in that it may reduce antibody-induced therapy failure. But, long-term comparative trials in naïve patients between Xeomin(®) and conventional BoNT/A drugs are required to confirm the low immunogenicity of Xeomin(®). |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 30 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 1 | 3% |
| India | 1 | 3% |
| Peru | 1 | 3% |
| Unknown | 27 | 90% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 7 | 23% |
| Student > Bachelor | 3 | 10% |
| Student > Doctoral Student | 2 | 7% |
| Other | 2 | 7% |
| Student > Ph. D. Student | 2 | 7% |
| Other | 5 | 17% |
| Unknown | 9 | 30% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 14 | 47% |
| Agricultural and Biological Sciences | 4 | 13% |
| Neuroscience | 1 | 3% |
| Biochemistry, Genetics and Molecular Biology | 1 | 3% |
| Unknown | 10 | 33% |
Attention Score in Context
This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 16 April 2019.
All research outputs
#5,239,459
of 25,371,288 outputs
Outputs from Clinical Ophthalmology
#465
of 3,712 outputs
Outputs of similar age
#25,870
of 122,180 outputs
Outputs of similar age from Clinical Ophthalmology
#7
of 27 outputs
Altmetric has tracked 25,371,288 research outputs across all sources so far. Compared to these this one has done well and is in the 79th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,712 research outputs from this source. They receive a mean Attention Score of 4.9. This one has done well, scoring higher than 87% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 122,180 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 78% of its contemporaries.
We're also able to compare this research output to 27 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 74% of its contemporaries.